NASDAQ:ALXO ALX Oncology (ALXO) Stock Price, News & Analysis → Warren Buffett & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad) Free ALXO Stock Alerts $9.01 -0.27 (-2.91%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$8.80▼$9.4050-Day Range$8.37▼$17.5652-Week Range$3.94▼$17.83Volume860,089 shsAverage Volume816,374 shsMarket Capitalization$469.42 millionP/E RatioN/ADividend YieldN/APrice Target$18.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ALX Oncology alerts: Email Address ALX Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside109.0% Upside$18.83 Price TargetShort InterestBearish11.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.73Based on 7 Articles This WeekInsider TradingSelling Shares$1.61 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.89) to ($2.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.55 out of 5 starsMedical Sector407th out of 904 stocksPharmaceutical Preparations Industry188th out of 429 stocks 3.4 Analyst's Opinion Consensus RatingALX Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageALX Oncology has only been the subject of 2 research reports in the past 90 days.Read more about ALX Oncology's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.56% of the float of ALX Oncology has been sold short.Short Interest Ratio / Days to CoverALX Oncology has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in ALX Oncology has recently increased by 6.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldALX Oncology does not currently pay a dividend.Dividend GrowthALX Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALXO. Previous Next 2.6 News and Social Media Coverage News SentimentALX Oncology has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for ALX Oncology this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added ALX Oncology to their MarketBeat watchlist in the last 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ALX Oncology insiders have sold 3,137.84% more of their company's stock than they have bought. Specifically, they have bought $49,764.00 in company stock and sold $1,611,280.00 in company stock.Percentage Held by Insiders33.40% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.97% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ALX Oncology's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ALX Oncology are expected to grow in the coming year, from ($2.89) to ($2.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ALX Oncology is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ALX Oncology is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioALX Oncology has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ALX Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe new masters of energyAccording to one source, this new grid could soon provide energy to “one billion people in the world who don’t have access to electricity right now.” And early investors could make a fortune.Click here to get all the details. About ALX Oncology Stock (NASDAQ:ALXO)ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Read More ALXO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALXO Stock News HeadlinesJune 7 at 8:26 AM | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 20,000 SharesMay 16, 2024 | insidertrades.comInsider Selling: ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells 12,000 Shares of StockMay 9, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells $318,400.00 in StockJune 6 at 1:22 AM | americanbankingnews.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 2, 2024 | globenewswire.comALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder CancerJune 2, 2024 | americanbankingnews.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Increase in Short InterestMay 31, 2024 | americanbankingnews.comALX Oncology (NASDAQ:ALXO) Stock Rating Reaffirmed by Cantor FitzgeraldMay 29, 2024 | globenewswire.comALX Oncology Announces Participation in the Jefferies Global Healthcare ConferenceMay 24, 2024 | markets.businessinsider.comBuy Rating for ALX Oncology Amid Impressive Evorpacept and Padcev Combination Trial ResultsMay 16, 2024 | finance.yahoo.comInsider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells SharesMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), ALX Oncology Holdings (ALXO) and Quoin Pharmaceuticals (QNRX)May 10, 2024 | finance.yahoo.comALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...May 10, 2024 | investorplace.comALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024May 9, 2024 | globenewswire.comALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | globenewswire.comALX Oncology Appoints Allison Dillon as Chief Business OfficerMay 3, 2024 | msn.comRelay Therapeutics GAAP EPS of -$0.62 beats by $0.10, revenue of $10.01M beats by $9.09MApril 30, 2024 | finance.yahoo.comALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal CancerApril 24, 2024 | globenewswire.comALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual MeetingApril 20, 2024 | investing.comAlx Oncology's president & CSO sells $710k in stockApril 18, 2024 | seekingalpha.comALX Oncology: Trying To Justify The HypeApril 18, 2024 | seekingalpha.comENPH, OCUL and ITCI are among after hour moversApril 13, 2024 | uk.investing.comALX Oncology hold rating reiterated with steady stock target by StifelApril 11, 2024 | markets.businessinsider.comBuy Rating on ALX Oncology Holdings Amid Strong Clinical Data and Favorable rNPV AnalysisApril 9, 2024 | globenewswire.comALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)April 8, 2024 | markets.businessinsider.comBuy Rating Justified by Promising Evorpacept Trial Results and Market PotentialSee More Headlines Receive ALXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/08/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALXO CUSIPN/A CIK1810182 Webwww.alxoncology.com Phone650-466-7125FaxN/AEmployees72Year FoundedN/APrice Target and Rating Average Stock Price Target$18.83 High Stock Price Target$27.00 Low Stock Price Target$11.00 Potential Upside/Downside+109.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-90.41% Return on Assets-72.16% Debt Debt-to-Equity Ratio0.06 Current Ratio5.21 Quick Ratio5.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.81 per share Price / Book2.36Miscellaneous Outstanding Shares52,100,000Free Float34,699,000Market Cap$469.42 million OptionableOptionable Beta1.15 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Corey S. Goodman Ph.D. (Age 72)Executive Chairman Comp: $84kMr. Jason W. Lettmann (Age 47)CEO & Director Comp: $60.5kDr. Jaume Pons Ph.D. (Age 57)Founder, President, Director & Chief Scientific Officer Comp: $856.29kMr. Peter S. Garcia M.B.A. (Age 62)Chief Financial Officer Comp: $631.11kDr. Sophia Randolph M.D. (Age 56)Ph.D., Chief Medical Officer & Director Comp: $637.24kDr. Michael Chang Ph.D.Vice President of OperationsMs. Shelly Pinto (Age 47)Senior VP of Finance & Chief Accounting Officer Comp: $508.26kDr. Christopher Byrd J.D.Ph.D., General CounselDr. Athanasios Tsiatis M.D.Senior Vice President of Clinical DevelopmentDr. Lin Yeong-Liang M.D.M.S., Senior Vice President of Drug Safety & PharmacovigilanceMore ExecutivesKey CompetitorsAtea PharmaceuticalsNASDAQ:AVIRI-MabNASDAQ:IMABEvotecNASDAQ:EVOProtagonist TherapeuticsNASDAQ:PTGXNewAmsterdam PharmaNASDAQ:NAMSView All CompetitorsInsiders & InstitutionsJaume PonsSold 20,000 sharesTotal: $168,600.00 ($8.43/share)Redmile Group LLCBought 667,245 shares on 5/16/2024Ownership: 8.304%California State Teachers Retirement SystemBought 18,360 shares on 5/16/2024Ownership: 0.044%Price T Rowe Associates Inc. MDSold 310,474 shares on 5/15/2024Ownership: 0.447%EntryPoint Capital LLCBought 2,847 shares on 5/14/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions ALXO Stock Analysis - Frequently Asked Questions Should I buy or sell ALX Oncology stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALXO shares. View ALXO analyst ratings or view top-rated stocks. What is ALX Oncology's stock price target for 2024? 6 Wall Street analysts have issued 12 month price objectives for ALX Oncology's shares. Their ALXO share price targets range from $11.00 to $27.00. On average, they predict the company's share price to reach $18.83 in the next year. This suggests a possible upside of 109.0% from the stock's current price. View analysts price targets for ALXO or view top-rated stocks among Wall Street analysts. How have ALXO shares performed in 2024? ALX Oncology's stock was trading at $14.89 on January 1st, 2024. Since then, ALXO stock has decreased by 39.5% and is now trading at $9.01. View the best growth stocks for 2024 here. Are investors shorting ALX Oncology? ALX Oncology saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 3,360,000 shares, an increase of 6.3% from the April 30th total of 3,160,000 shares. Based on an average daily trading volume, of 546,100 shares, the short-interest ratio is currently 6.2 days. Currently, 11.6% of the company's shares are sold short. View ALX Oncology's Short Interest. When is ALX Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ALXO earnings forecast. How were ALX Oncology's earnings last quarter? ALX Oncology Holdings Inc. (NASDAQ:ALXO) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.87) by $0.16. What ETF holds ALX Oncology's stock? Inspire Small/Mid Cap ETF holds 34,771 shares of ALXO stock, representing 0.24% of its portfolio. What other stocks do shareholders of ALX Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and When did ALX Oncology IPO? ALX Oncology (ALXO) raised $128 million in an initial public offering (IPO) on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager. Who are ALX Oncology's major shareholders? ALX Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Redmile Group LLC (8.30%), Vanguard Group Inc. (3.13%), Price T Rowe Associates Inc. MD (0.45%), Los Angeles Capital Management LLC (0.20%), Swiss National Bank (0.09%) and Inspire Investing LLC (0.07%). Insiders that own company stock include Jason Lettmann, Jaume Pons, Lsv Associates, Llc, Peter S Garcia, Peter S Garcia, Shelly Pinto and Sophia Randolph. View institutional ownership trends. How do I buy shares of ALX Oncology? Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALXO) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredWarren Buffett & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.